Does it match the label? Community Testing System Bulletin
January – June 2026 · IPED Trends Series
The Community Testing System is the arm of ROIDTrends that uses community-submitted drug checking results to understand IPED markets across Australia and New Zealand. This bulletin reports on 612 samples tested by consumers with PEDTest reagent kits between January and June 2026, showing what compounds were likely present and how often products matched their label. Reagent tests indicate the likely presence of a compound, not its purity or dose, so results should be read as a signal of market trends.
Key Findings
Key Takeaways
- Fewer than half (47.1%; 288 of 612) of samples matched what the label reported, and about one third (31.7%) were swapped for another compound.
- Primobolan (methenolone enanthate) was rarely confirmed as labelled (10.9%). In 43 samples it contained Masteron instead, 61% of all identified substitutions.
- 85.7% (18 of 21) of hGH samples were confirmed as hGH, but reagent tests confirm presence, not dose. A confirmed vial can still hold more or less than labelled.
Recommended Citation
Akrigg K., Bonenti B., Ferris J., Harris P., Hughes E., Craven A., Davey G., Kill E., Weith S., Piatkowski T. ROIDTrends Community Testing System Bulletin, January 2026 – June 2026. IPED Trends Series. UQ, Queensland; 2026. DOI: https://doi.org/10.14264/1d427ec
Funding
ROIDTrends is funded by the Queensland Mental Health Commission.
Copyright
This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager.